
Ziarco appoints John LaMattina as R&D advisor
pharmafile | March 20, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | LaMattina, Ziarco
Ex-global head of Pfizer R&D and Pharmafocus regular John LaMattina has been given a strategic advisory role by biotech firm Ziarco.
LaMattina is the former senior VP of Pfizer and president of its global research and development. In this role, LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the US, Europe and Asia.
He retired from this position in December, 2007. LaMattina spent 30 years at Pfizer having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including VP of US Discovery Operations in 1993, senior VP of Worldwide Discovery Operations in 1998 and senior VP of Worldwide Development in 1999.
During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. LaMattina is the author of numerous scientific publications and holds a number of US Patents. In addition, he is the author of Wiley books: “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?”. He also writes regularly for Forbes.
Related Content

Novartis acquires Ziarco adding to dermatology pipeline
Novartis has announced that it will acquire UK-based Ziarco, to add Ziarco’s lead investigational oral …

FDA approvals: 1996 versus 2014
As highlighted in a number of recent stories, 2014 was a banner year for the …

Drug prices defy gravity – until patent expiry
How drugs are priced is a hot topic these days, and a new Bloomberg article …






